Clinical Study Of Levosimendan Treatment Of Acute Coronary Syndrome And Acute Heart Failure

Objective Discussion levosimendan treatment of acute coronary syndrome(ACS)complicated with acute heart failure(AHF)clinical efficacy and safety.Methods Prospective randomized control study selected 68 cases of ACS merger AHF patients were randomly divided into a control group and a treatment group 34 cases.All patients with heart failure treatment guidelines in accordance with standardized anti-heart failure treatment,the control group was added to dobutamine On this basis,the treatment group were treated with levosimendan.Comprehensive Observation of the efficacy of the two groups before and after treatment,left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac index(CI)pulmonary capillary wedge pressure(PCWP)and serum N-terminal B-type natriuretic peptide(NT-proBNP)changes.Followed up for 6 months,cardiac mortality was observed before and after treatment,the rate of hospitalization for heart failure,the difference between the composite end point of cardiovascular events again.Comprehensive evaluation of drug efficacy and safety.Results After treatment,24h,72h after former LVEF,SV,Cl,PCWP,NT-proBNP levels than treatment vary significantly(P<0.05),and the treatment group than the control group index(P<0.05),the treatment of 24h clinical evaluation of the treatment group than the control group(P<0.05).Levosimendan drug-related adverse events did not occur,follow-up of 1 month levosimendan composite endpoint than dobutamine group(P<0.05).Follow-up 3,6 months,no significant difference between the two groups composite endpoint(P>0.05).Conclusion Levosimendan can significantly alleviate acute heart failure in the short term illness and improve their symptoms and reduce short-term cardiac accidents occur,can improve long-term prognosis is for further study.